Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 18th Annual Perspectives in Breast Cancer New York, NY 18 August 2012 Treatment Decision Making for DCIS Monica Morrow MD Chief, Breast Surgery Service Anne Burnett Windfohr Chair of Clinical Oncology Memorial Sloan-Kettering Cancer Center Controversies in DCIS Management • Is nipple sparing mastectomy appropriate? • Is RT necessary for all DCIS? • When is SN biopsy indicated? • What about endocrine rx? Mastectomy in DCIS • Indicated when DCIS is too extensive to be encompassed with a cosmetic resection. • Outcome Metaanalysis 21 studies, 1574 patients Local recurrence 1.4% (0.7-2.1%) Skin sparing mastectomy n = 223 Local recurrence 3.1% Boyages J, Cancer 1999;85:616 Carlson G, JACS 2007;204:1074 What About Nipple Sparing Mastectomy? Concerns • NSM leaves behind ductal tissue + breast tissue in order to preserve blood supply. • Occult nipple involvement present in 6-31% of cancers. • Most studies of NSM are in invasive cancer. 10/26/2011 Clinical Outcomes NSM European Institute of Oncology 3/02-12/07 Median f/u: 50 months All patients received 16 Gy to NAC Invasive Cancer DCIS 772 162 Breast 3.6% 4.9% NAC 0.8% 2.9% # Cases 5yr LR CAUTION: At 20 mo f/u, no NAC recurrences, 1.4% LR Petit JY, Ann Oncol 2012;23:2053-8 Petit JY, Br Ca Res Treat 2009;117:333 NSM in DCIS • Increased risk of LR due to retained breast tissue and poor exposure. • Contraindicated in patients with extensive DCIS necessitating mastectomy, localized DCIS in subareolar space. What do I really think about NSM? It’s a great operation for a woman who doesn’t actually need a mastectomy. Is RT Necessary for All DCIS? Randomized Trials of Excision ± RT in DCIS Trial NSABP B17 EORTC 10853 UK/ANZ Swedish # Patients % Mammo Detected Boost Tamoxifen 813 1002 80 71 No No No No 1030 100 No Yes 1046 78 No No Metaanalysis Trials of Excision ± RT in DCIS n = 3729 10 yr IBTR Total Invasive DCIS No RT RT p-value 28.1% 15.4% 14.9% 12.9% 6.8% 6.5% < .001 < .001 < .001 EBCTCG JNCI Monograph 2010;41:162 Metaanalysis Trials of Excision ± RT in DCIS 10 yr Survival Outcomes All deaths Death w/o recurrence Cardiac death EBCTCG JNCI Monograph 2010;41:162 No RT RT p-value 8.2 5.7 1.3 8.4 5.4 1.5 > .1 > .1 > .1 Conclusions of Randomized Trials • RT reduces the risk of LR by 50%. • Patient subsets NOT benefitting from RT have not been identified. Academic U.S. Physicians Recommending RT For DCIS Ceilley E, Cancer 2004;101:1958 Concerns Regarding Randomized Trials • Detailed tissue processing/method of pathology evaluation not specified. • Post-excision mammography not mandated. • Impact of margin width on RT benefit not assessed. Does wide excision + detailed pathology exam result in local control equivalent to excision + RT? Local Recurrence: Margins ≥ 10 mm Silverstein M, NEJM 1999;340:1455 E5194: Excision Alone ± Tamoxifen for DCIS Eligibility • DCIS ≥ 3mm in size • Minimum margin width ≥ 3mm • Specimen completely embedded, sequentially sectioned • Post-excision mammogram free of calcification Hughes L, J Clin Oncol 2009;27:5319 Patient Characteristics: E5194 Low/Int Grade High Grade Number 579 101 Median Size Margin ≥ 1cm Margin ≥ 5mm TAM planned 6mm 46% 67% 31% 7mm 48% 75% 31% Hughes L, J Clin Oncol 2009;27:5319 Intergroup Trial of Excision Alone Mean f/u 6.3 years High Grade Low Grade 5yr 15.3% 6.1% 7yr 18.0% (10.2-25.9) 10.5% (7.5-13.6) 5yr 3.9% 3.7% 7yr 7.4% (1.4-13.5) 4.8% (2.7-6.9) IBTR Contralateral Hughes L, J Clin Oncol 2009;27:5319 Local Failure According to Pathology After Lumpectomy and Radiation Solin L, J Clin Oncol 1996;14:754 Effect of Margin Width – No RT Intergroup Trial % Local Recurrence Margin Low Grade High Grade < 1cm 5.6 14.8 ≥ 1cm 6.7 15.9 Hughes L, J Clin Oncol 2009;27:5319 RTOG 9084: RT vs Observation for “Good Risk” DCIS Eligibility • • • • Mammographic or incidental DCIS Low or intermediate grade Size (mammographic) ≤ 2.5 cm Margins ≥ 3 mm McCormick B, ASCO 2012 RTOG 9084 Schema Stratify Age < 50 ≥ 50 Margins Negative re-excision 3-9 mm ≥ 10 mm Size ≤ 1 cm > 1 cm-2.5 cm Grade Low Intermediate Tamoxifen No Yes R A N D O M I Z E Observation RT No Boost Patient Characteristics: RTOG 9084 Observation RT Number 298 287 Median Age 58 58 72.8% 72.1% 44% 42.2% Margin 3-9 mm ≥ 10 mm Neg. re-excision 35.6% 16.1% 48.3% 36.2% 15.7% 48.1% Intent to use Tam Yes 69.5% 68.6% Mammographic size < 1 cm Grade 1 McCormick B, ASCO 2012 Local Failure Ipsilateral Breast 30 FailedTotal Observation 15 298 2 287 RT Local Failure (%) 25 20 Gray's test p-value=0.0022 HR = 0.14 (0.03,0.61) 15 10 5-Years Rates: 3.2% 5 0.4% 0 0 Patients at Risk Observation 298 RT 287 2 4 Years after Randomization 272 264 232 228 6 147 141 Local Recurrence After Excision +/- RT in Good Prognosis DCIS 5 yr LR Excision Alone E5194 6.1% RTOG 9084 3.2% Hughes L, J Clin Oncol 2009;27:5319 McCormick B, ASCO 2012 Excision + RT RTOG 9084 0.4% Conclusions E5194 + RTOG 9084 • Rates of LR after excision alone differed significantly among 2 populations with “favorable” DCIS selected with standard histopathologic criteria. • Benefit for RT is present even in this good-risk subset. A QUANTITATIVE MULTIGENE RT-PCR ASSAY FOR PREDICTING RECURRENCE RISK AFTER SURGICAL EXCISION ALONE WITHOUT IRRADIATION FOR DUCTAL CARCINOMA IN SITU (DCIS): A PROSPECTIVE VALIDATION STUDY OF THE DCIS SCORE FROM ECOG E5194 Solin LJ, Gray R, Baehner FL, Butler S, Badve S, Yoshizawa C, Shak S, Hughes L, Sledge G, Davidson N, Perez EA, Ingle J, Sparano J, Wood W Eastern Cooperative Oncology Group (ECOG) North Central Cancer Treatment Group (NCCTG) Genomic Health, Inc (GHI) 2011 San Antonio Breast Cancer Symposium DCIS Recurrence Score: Unanswered Questions • Do patients in the low-risk group benefit from RT? Is it predictive as well as prognostic? • Does it apply to the wider population of women with DCIS? • Validation needed Sentinel Node Biopsy in DCIS • DCIS lacks the ability to metastasize. • Rationale for axillary surgery is risk of unsampled invasive cancer. • ~15% risk of invasion after core bx diagnosis of DCIS. Risk of Axillary Recurrence in DCIS NSABP B17: 7 of 623 pts with axillary recurrence 1 s/p axillary dissection 3 with invasive IBTR 3 of 620 with DCIS at 15 yrs NSABP B24: 6 of 1799 pts at 11.6 yrs 1 with undiagnosed microinvasion Julian, Ann Surg Oncol 2006 Risk of Axillary Recurrence in DCIS Treatment years Lumpectomy Only L+XRT B17 L+XRT B24 L+XRT+TAM Julian, Ann Surg Oncol 2006 Rate/1000 pt 0.76 0.86 0.49 0.46 When Should Axillary Nodes Be Examined in DCIS? • Microinvasive carcinoma Metastases in 3% - 20% of cases. • DCIS treated by mastectomy. Opportunity lost if invasion found. • Done as a second procedure if invasion found after lumpectomy. Prior biopsy does not interfere with mapping. Benefit of Tamoxifen in ER+ DCIS NSABP B24 n = 732 Any Breast Cancer Event Any Invasive Cancer HR 0.58 0.53 p-value .0015 .005 Contralateral Cancer 0.50 .02 Allred DC, J Clin Oncol 2012;30:1268-73 Other Therapies in DCIS • Exemestane MAP 3 — 112 of 4560 had DCIS HR 0.47 (95% CI, 0.27-0.79) No subset analysis • Data on other AIs coming from NSABP B35, IBIS II • Raloxifene Equivalent to tamoxifen in STAR overall, better sideeffect profile DCIS analysis RR 1.46 (95% CI, 0.90-2.41) Goss PE, NEJM 2011;364:2381-91 Vogel VJ, JNCI Monogr 2010:181-6 Conclusions: Endocrine Rx • Endocrine therapy is an option for women desiring to minimize future breast cancer events. • Most favorable risk-benefit ratio is in premenopausal women with 2 breasts.